121 related articles for article (PubMed ID: 10753725)
41. Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells.
Lazdina U; Cao T; Steinbergs J; Alheim M; Pumpens P; Peterson DL; Milich DR; Leroux-Roels G; Sällberg M
J Virol; 2001 Jul; 75(14):6367-74. PubMed ID: 11413303
[TBL] [Abstract][Full Text] [Related]
42. A humanized antibody with specificity for hepatitis B surface antigen.
Ryu CJ; Padlan EA; Jin BR; Yoo OJ; Hong HJ
Hum Antibodies Hybridomas; 1996; 7(3):113-22. PubMed ID: 9057059
[TBL] [Abstract][Full Text] [Related]
43. Three monoclonal antibodies to the VHS virus glycoprotein: comparison of reactivity in relation to differences in immunoglobulin variable domain gene sequences.
Lorenzen N; Cupit PM; Secombes CJ; Cunningham C
Fish Shellfish Immunol; 2000 Feb; 10(2):129-42. PubMed ID: 10938729
[TBL] [Abstract][Full Text] [Related]
44. The inhibition of lung cancer cell growth by intracellular immunization with LC-1 ScFv.
Chen L; Li G; Tang L; Wang J; Ge XR
Cell Res; 2002 Mar; 12(1):47-54. PubMed ID: 11942410
[TBL] [Abstract][Full Text] [Related]
45. Development of a biotin mimic tagged ScFv antibody against western equine encephalitis virus: bacterial expression and refolding.
Das D; Kriangkum J; Nagata LP; Fulton RE; Suresh MR
J Virol Methods; 2004 May; 117(2):169-77. PubMed ID: 15041214
[TBL] [Abstract][Full Text] [Related]
46. Cytoplasmic trafficking of the canine parvovirus capsid and its role in infection and nuclear transport.
Vihinen-Ranta M; Yuan W; Parrish CR
J Virol; 2000 May; 74(10):4853-9. PubMed ID: 10775624
[TBL] [Abstract][Full Text] [Related]
47. Expression of Aleutian mink disease parvovirus capsid proteins in defined segments: localization of immunoreactive sites and neutralizing epitopes to specific regions.
Bloom ME; Martin DA; Oie KL; Huhtanen ME; Costello F; Wolfinbarger JB; Hayes SF; Agbandje-McKenna M
J Virol; 1997 Jan; 71(1):705-14. PubMed ID: 8985402
[TBL] [Abstract][Full Text] [Related]
48. Induction of neutralizing antibodies by a tobacco chloroplast-derived vaccine based on a B cell epitope from canine parvovirus.
Molina A; Veramendi J; Hervás-Stubbs S
Virology; 2005 Nov; 342(2):266-75. PubMed ID: 16140352
[TBL] [Abstract][Full Text] [Related]
49. Cloning and expression of functional single-chain Fv antibodies directed against NIa and coat proteins of potato virus Y.
Rouis S; Lafaye P; Jaoua-Aydi L; Sghaier Z; Ayadi H; Gargouri-Bouzid R
J Virol Methods; 2006 Oct; 137(1):1-6. PubMed ID: 16884787
[TBL] [Abstract][Full Text] [Related]
50. Virus neutralization by germ-line vs. hypermutated antibodies.
Kalinke U; Oxenius A; Lopez-Macias C; Zinkernagel RM; Hengartner H
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10126-31. PubMed ID: 10963674
[TBL] [Abstract][Full Text] [Related]
51. The VP1 N-terminal sequence of canine parvovirus affects nuclear transport of capsids and efficient cell infection.
Vihinen-Ranta M; Wang D; Weichert WS; Parrish CR
J Virol; 2002 Feb; 76(4):1884-91. PubMed ID: 11799183
[TBL] [Abstract][Full Text] [Related]
52. Fine mapping of canine parvovirus B cell epitopes.
López de Turiso JA; Cortés E; Ranz A; García J; Sanz A; Vela C; Casal JI
J Gen Virol; 1991 Oct; 72 ( Pt 10)():2445-56. PubMed ID: 1919526
[TBL] [Abstract][Full Text] [Related]
53. Isolation, cloning and analysis of parvovirus-specific canine antibodies from peripheral blood B cells.
Früh SP; Adu OF; López-Astacio RA; Weichert WS; Wasik BR; Parrish CR
Dev Comp Immunol; 2023 Oct; 147():104894. PubMed ID: 37467826
[TBL] [Abstract][Full Text] [Related]
54. Assaying for structural variation in the parvovirus capsid and its role in infection.
Weichert WS; Parker JS; Wahid AT; Chang SF; Meier E; Parrish CR
Virology; 1998 Oct; 250(1):106-17. PubMed ID: 9770425
[TBL] [Abstract][Full Text] [Related]
55. The structure of a neutralized virus: canine parvovirus complexed with neutralizing antibody fragment.
Wikoff WR; Wang G; Parrish CR; Cheng RH; Strassheim ML; Baker TS; Rossmann MG
Structure; 1994 Jul; 2(7):595-607. PubMed ID: 7522904
[TBL] [Abstract][Full Text] [Related]
56. Canine parvovirus host range is determined by the specific conformation of an additional region of the capsid.
Parker JS; Parrish CR
J Virol; 1997 Dec; 71(12):9214-22. PubMed ID: 9371580
[TBL] [Abstract][Full Text] [Related]
57. A neutralizing monoclonal antibody to bovine rotavirus VP8 neutralizes rotavirus infection without inhibiting virus attachment to MA-104 cells.
Lee J; Babiuk LA; Yoo D
Can J Vet Res; 1998 Jan; 62(1):63-7. PubMed ID: 9442942
[TBL] [Abstract][Full Text] [Related]
58. Monoclonal antibodies that distinguish antigenic variants of canine parvovirus.
Nakamura M; Nakamura K; Miyazawa T; Tohya Y; Mochizuki M; Akashi H
Clin Diagn Lab Immunol; 2003 Nov; 10(6):1085-9. PubMed ID: 14607871
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of canine parvovirus 2 (CPV-2) replication by TAT-scFv through targeting of the viral structural protein VP2 of CPV-2.
Liu K; Xu P; Li Y; Qin J; Zhu J; Li Y
New Microbiol; 2024 Jan; 46(4):381-389. PubMed ID: 38252049
[TBL] [Abstract][Full Text] [Related]
60. Development of a second generation monoclonal single chain variable fragment antibody against Venezuelan equine encephalitis virus: expression and functional analysis.
Alvi AZ; Fulton RE; Chau D; Suresh MR; Nagata LP
Hybrid Hybridomics; 2002 Jun; 21(3):169-78. PubMed ID: 12165142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
